Xenon制药(XENE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

XENE Xenon制药

交易中 04-16 15:44:09 EDT

58.16

-0.72

-1.23%

最高58.88	最低57.82	成交量66.15万
今开58.88	昨收58.88	日振幅1.80%
总市值55.50亿	流通市值52.28亿	总股本9,543万
成交额3,847万	换手率0.74%	流通股本8,989万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"XENE","market":"US","secType":"STK","nameCN":"Xenon制药","latestPrice":58.155,"timestamp":1776368648560,"preClose":58.88,"halted":0,"volume":661496,"delay":0,"changeRate":-0.01231317934782611,"floatShares":89889500,"shares":95427200,"eps":-4.364588,"marketStatus":"交易中","change":-0.725,"latestTime":"04-16 15:44:09 EDT","open":58.88,"high":58.88,"low":57.82,"amount":38465279.307312,"amplitude":0.018003,"askPrice":58.2,"askSize":6,"bidPrice":58.14,"bidSize":101,"shortable":3,"etf":0,"ttmEps":-4.364588,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1776369600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1415163600000,"exchange":"NASDAQ","adjPreClose":58.88,"preHourTrading":{"tag":"盘前","latestPrice":58.88,"preClose":58.88,"latestTime":"09:25 EDT","volume":1269,"amount":74434.316796,"timestamp":1776345900156,"change":0,"changeRate":0,"amplitude":0.013247},"postHourTrading":{"tag":"盘后","latestPrice":58.88,"preClose":58.88,"latestTime":"16:10 EDT","volume":17911,"amount":1054599.68,"timestamp":1776283808877,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.927683,"impliedVol":0.4226,"impliedVolPercentile":0.32},"requestUrl":"/m/hq/s/XENE","defaultTab":"news","newsList":[{"id":"1197205671","title":"Xenon制药普通股发行价定为每股57美元；预融资认股权证定价56.9999美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197205671","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197205671?lang=zh_cn&edition=full","pubTime":"2026-03-11 10:40","pubTimestamp":1773196814,"startTime":"0","endTime":"0","summary":"Xenon制药公司宣布其普通股发行价格确定为每股57.00美元。与此同时，该公司推出的预融资认股权证定价为每股56.9999美元。此次发行旨在为公司的研发项目及运营需求提供资金支持。\n通过本次融资，Xenon制药计划进一步推进其在神经科学领域的创新疗法开发。市场观察人士指出，此次定价反映了投资者对该公司长期增长潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618241856","title":"美股异动 | 癫痫药三期取得积极结果 Xenon制药(XENE.US)开盘飙升超42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618241856","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618241856?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:58","pubTimestamp":1773064702,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，Xenon制药(XENE.US)开盘飙升超42%，报59.59美元。消息面上，3月9日，该公司公布Azetukalner治疗局灶性癫痫的3期X-TOLE2研究达到主要终点，25mg剂量组中位发作频率降低53.2%，安慰剂组为10.4%，p值0.000000000006。该公司确认Azetukalner安全性特征与前期研究一致，耐受性良好，并宣布计划于2026年第三季度向美国FDA提交Azetukalner的新药申请。此外，威廉博莱分析师Myles Minter维持Xenon制药买入评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 癫痫药三期取得积极结果 Xenon制药(XENE.US)开盘飙升超42%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["XENE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618939689","title":"Xenon制药盘中异动 股价大涨39.14%报58.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939689","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618939689?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:31","pubTimestamp":1773063092,"startTime":"0","endTime":"0","summary":"北京时间2026年03月09日21时31分，Xenon制药股票出现波动，股价大幅拉升39.14%。截至发稿，该股报58.36美元/股，成交量316.658万股，换手率3.81%，振幅6.44%。Xenon制药股票所在的生物技术行业中，整体跌幅为0.20%。其相关个股中，Relmada Therapeutics, Inc.、Xenon制药、Lisata Therapeutics, Inc.涨幅较大，Relmada Therapeutics, Inc.、Moolec Science Sa、Quince Therapeutics, Inc.较为活跃，换手率分别为29.98%、18.75%、13.13%，振幅较大的相关个股有Aditxt, Inc.、Uniqure N.V.、Edesa Biotech, Inc.，振幅分别为17.03%、11.91%、9.82%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213132a6b2ab78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213132a6b2ab78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116806366","title":"Xenon制药高管：四种标注剂量（10、15、20及25毫克）将实行统一价格，便于医生起始及递增用药——电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1116806366","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116806366?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:55","pubTimestamp":1773060914,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals高管在电话会议中透露，其产品所有四种标注剂量——10毫克、15毫克、20毫克和25毫克——将采用统一价格策略。这一举措旨在为临床医生提供更大灵活性，使其能够根据患者具体情况，从较低剂量开始治疗并逐步调整至更高剂量，而无需担心价格差异带来的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120269451","title":"Xenon制药高管称公司对Azetukalner上市前景信心十足","url":"https://stock-news.laohu8.com/highlight/detail?id=1120269451","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120269451?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:34","pubTimestamp":1773059693,"startTime":"0","endTime":"0","summary":"在最新电话会议中，Xenon制药管理层透露，公司已为新型药物Azetukalner的上市做好充分准备。高管强调，凭借现有的市场策略和资源储备，Xenon制药将处于极具优势的竞争地位。这一表态凸显了公司对该产品商业化前景的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123470020","title":"Xenon制药癫痫药物晚期试验达主要终点 盘前股价飙升16.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123470020","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123470020?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:28","pubTimestamp":1773055707,"startTime":"0","endTime":"0","summary":"Xenon制药开发的癫痫治疗药物在关键性三期临床试验中成功达到主要研究终点，这一突破性进展推动其股价在盘前交易时段大幅攀升16.5%。该试验结果标志着公司向监管部门提交新药申请迈出关键一步，也为难治性癫痫患者带来新的治疗希望。临床试验数据显示，与安慰剂组相比，接受Xenon制药实验性药物治疗的患者群体在癫痫发作频率方面呈现统计学显著改善。受此消息提振，投资者对Xenon制药未来发展前景展现强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167466546","title":"Xenon制药公布Azetukalner治疗局灶性癫痫发作3期X-Tole2研究积极顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1167466546","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167466546?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:02","pubTimestamp":1773054177,"startTime":"0","endTime":"0","summary":"Xenon制药宣布，其针对局灶性癫痫发作（FOS）的研究药物Azetukalner，在关键3期临床试验X-Tole2中获得了积极的顶线结果。该数据标志着公司在癫痫治疗领域研发的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127133254","title":"Xenon制药预计2026年第三季度向美国FDA提交Azetukalner治疗局灶性癫痫发作的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1127133254","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127133254?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:02","pubTimestamp":1773054144,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. 近日公布其研发进展，公司计划于2026年第三季度向美国食品药品监督管理局（FDA）正式提交Azetukalner（XEN1101）用于治疗局灶性癫痫发作（Focal Onset Seizures, FOS）的新药申请（NDA）。这一关键里程碑标志着该药物在癫痫治疗领域的开发进入重要阶段。\nAzetukalner是一种新型钾通道开放剂，其III期临床研究已展现出显著疗效与良好安全性。若获批上市，该药物有望为全球数百万局灶性癫痫患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133006756","title":"Xenon制药将于2026年3月9日公布Azetukalner治疗局灶性发作的3期X-Tole2研究顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1133006756","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133006756?lang=zh_cn&edition=full","pubTime":"2026-03-09 02:01","pubTimestamp":1772992873,"startTime":"0","endTime":"0","summary":"Xenon制药宣布，计划于2026年3月9日（星期一）公布其候选药物Azetukalner针对局灶性发作性癫痫的3期临床试验X-Tole2研究的顶线结果。此次结果发布备受业界关注，将为评估该药物疗效与安全性的关键数据提供重要参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195254737","title":"Xenon制药宣布根据纳斯达克规则授予新员工股权激励","url":"https://stock-news.laohu8.com/highlight/detail?id=1195254737","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195254737?lang=zh_cn&edition=full","pubTime":"2026-01-17 05:07","pubTimestamp":1768597639,"startTime":"0","endTime":"0","summary":"温哥华与波士顿2026年1月16日电——专注于神经科学领域的生物制药公司Xenon Pharmaceuticals Inc.今日宣布，向十名新任非高管员工授予总计42,300份股票期权作为股权激励。上述期权均由公司董事会薪酬委员会批准，授予日期为2026年1月15日，此举符合纳斯达克上市规则5635条中关于新员工入职重要激励条款的规定。此次授予的股票期权行权价为每股40.74美元，与Xenon普通股在授予日的收盘价持平。Xenon总部位于加拿大不列颠哥伦比亚省温哥华与美国马萨诸塞州波士顿。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ81514606.USD","LU2461242641.AUD","LU0545562505.USD","GB00B4LPDJ14.GBP","SG9999018857.SGD","IE00B19Z8W00.USD","BK4585","LU0444971666.USD","GB00B4QBRK32.GBP","LU0823434583.USD","BK4106","LU0823417737.USD","LU0965509101.SGD","XENE","LU0889565833.HKD","LU2471134952.CNY","LU1823568750.SGD","LU2404859741.USD","LU0861579265.USD","BK4581","LU0289960550.SGD","LU1037948541.HKD","LU1633808545.USD","LU0868494708.USD","LU0225283273.USD","LU0472753341.HKD","LU0256863902.USD","LU0823417653.USD","LU1642822529.SGD","LU1236620750.USD","LU2471134879.HKD","LU1116320901.HKD","IE00BKVL7J92.USD","LU2125154935.USD","LU0158827948.USD","LU0528227936.USD","LU2023251221.USD","LU0965508806.USD","LU0708994859.HKD","LU1989772923.USD","LU1366333091.USD","LU1988902786.USD","SG9999018865.SGD","LU0079474960.USD","LU1267930730.SGD","LU2237438978.USD","LU2265009873.SGD","LU2720916845.USD","LU2750360997.AUD","BK4139","SG9999014906.USD","LU0823421333.USD","LU2111349929.HKD","LU0417517546.SGD","IE00B19Z9505.USD","BK4227","LU2361044949.HKD","LU2750360641.GBP","BK4588","LU0690374615.EUR","LU1069344957.HKD","LU0265550359.USD","LU1934455277.USD","LU2097829019.USD","LU0097036916.USD","LU0158827781.USD","LU2746668974.SGD","LU0187121727.USD","LU0672654240.SGD","LU0476273544.USD","LU2471134796.USD","LU1935042991.SGD","BK4527","SG9999017495.SGD","LU0444973449.USD","NQmain","LU0109392836.USD","LU0154236417.USD","LU2506951958.HKD","LU2028103732.USD","SG9999001424.SGD","LU0096362180.USD","LU2242649171.HKD","LU1935042215.USD","LU0965509283.SGD","LU0994945656.USD","LU1121112475.USD","LU0289941410.SGD","LU2506952170.USD","LU0642271901.SGD","LU0289961442.SGD","LU0127658192.USD","LU2764263039.SGD","LU1814569148.SGD","LU2361045086.USD","V","IE00B1XK9C88.USD","IE00B19Z8X17.USD","IE00BQXX3D17.EUR","LU2125154778.USD","LU2764262908.HKD","SG9999014880.SGD","LU1064131342.USD","LU2089283258.USD","LU2089284900.SGD","LU0106261372.USD","LU0061474960.USD","LU1935042488.USD","LU0109391861.USD","BK4535","LU0787776722.HKD","LU0048584097.USD","LU0823434740.USD","LU1037948897.HKD","LU1935043536.SGD","LU0690374961.EUR","LU0175139822.USD","LU0128525929.USD","LU0353189763.USD","LU0234572021.USD","LU0557290698.USD","LU0345774631.USD","LU0950375773.USD","LU0316494557.USD","LU0348723411.USD","LU0006306889.USD","LU2361044865.SGD","LU0029864427.USD","LU1228905037.USD","LU0289739343.SGD","LU0234570918.USD","LU0320765059.SGD","LU2506952097.USD","LU1435385759.SGD","LU2471134523.USD","LU0942090050.USD","SG9999000418.SGD","LU1043141123.HKD","LU1670628061.USD","LU0124676726.USD","LU1934455863.HKD","LU2764263203.CNY","LU0170899867.USD","BK4533","LU1236620834.HKD","LU1280957306.USD","LU2106854487.HKD","IE00BWXC8680.SGD","LU0345774391.USD","LU2271345857.HKD","LU1670627923.USD","LU0342679015.USD","IE00BQXX3F31.USD","LU1917777945.USD","LU2746668461.USD","LU0157215616.USD","SGXZ51526630.SGD","LU1804176565.USD","LU1712237335.SGD","LU1815336760.USD","LU2244417387.USD","LU1852331112.SGD","LU0354030511.USD","LU2087625088.SGD","LU1316542783.SGD","LU2326559502.SGD","LU2023250504.SGD","LU0057025933.USD","LU2264538146.SGD","LU0823421416.USD","LU1791710400.SGD","IE00BZ1G4Q59.USD","SGXZ31699556.SGD","LU0957791311.USD","LU0390134368.USD","LU0683600562.USD","IE00B1BXHZ80.USD","LU0511384066.AUD","LU2023250843.SGD","LU1116320737.USD","LU2506951875.HKD","SGXZ99366536.SGD","LU0069063385.USD","LU2360032135.SGD","LU1803068979.SGD","LU1035775433.USD","LU0353189680.USD","LU0708995401.HKD","LU0640476718.USD","LU0426412945.USD","LU0354030438.USD","LU1974910355.USD","LU0265550946.USD","LU1429558221.USD","SG9999014914.USD","LU0251132253.USD","LU1791710582.SGD","LU1043141396.HKD","LU1363072403.SGD","LU1934455194.USD","BK4598","BK4559","IE00BQXX3C00.GBP","LU1989772840.SGD","LU1623119135.USD","LU1691799644.USD","LU2404859667.USD","LU0310800379.SGD","LU0689626769.HKD","LU1228905540.USD","LU0971096721.USD","LU1935043023.USD","LU0965509010.AUD","SG9999014898.SGD","LU0215105999.USD","LU0868494617.USD","LU0957808578.USD","LU0426417589.USD","LU1046421795.USD","LU1267930573.SGD","LU0056508442.USD","LU1815333072.USD","BK4534","LU0256863811.USD","IE00BKDWB100.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1106102848","title":"新闻稿：Xenon制药根据纳斯达克上市规则5635(c)(4)报告诱导授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1106102848","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106102848?lang=zh_cn&edition=full","pubTime":"2025-12-05 06:23","pubTimestamp":1764886992,"startTime":"0","endTime":"0","summary":"加拿大不列颠哥伦比亚省温哥华和美国波士顿，2025年12月4日——Xenon制药公司是一家专注于神经科学的生物制药公司，致力于为有需要的患者进行药物发现、临床开发和变革性治疗的商业化。今日宣布对五名新非高管员工授予股权诱导，总计39,250个股票期权。所有期权均由公司董事会薪酬委员会批准，生效日期为2025年12月4日，且根据纳斯达克上市规则5635的规定，作为员工入职公司的重要诱因而授予。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2361044949.HKD","IE00B1XK9C88.USD","BK4227","LU2265009873.SGD","LU2360032135.SGD","LU2028103732.USD","BK4527","LU0868494617.USD","LU0889565833.HKD","LU0528227936.USD","LU2506952097.USD","LU0957791311.USD","LU1236620750.USD","LU0965509283.SGD","LU2125154935.USD","IE00BZ1G4Q59.USD","LU1043141396.HKD","LU2089284900.SGD","LU0069063385.USD","LU2746668974.SGD","LU1366333091.USD","LU2244417387.USD","BK4559","LU0353189763.USD","LU1935043023.USD","IE00BQXX3D17.EUR","LU0061474960.USD","LU0823421416.USD","LU0994945656.USD","LU1116320737.USD","LU1363072403.SGD","LU1989772840.SGD","LU1069344957.HKD","LU2361044865.SGD","LU0444973449.USD","LU0175139822.USD","LU0170899867.USD","LU0708995401.HKD","LU2506951875.HKD","LU1280957306.USD","LU2264538146.SGD","SGXZ99366536.SGD","LU1043141123.HKD","LU2125154778.USD","LU2361045086.USD","SG9999018857.SGD","LU0006306889.USD","LU2750360641.GBP","BK4581","LU0079474960.USD","LU0971096721.USD","LU2404859741.USD","SG9999014880.SGD","SG9999014898.SGD","SGXZ31699556.SGD","LU1935043536.SGD","SG9999017495.SGD","LU0048584097.USD","LU2271345857.HKD","LU0251132253.USD","LU0225283273.USD","LU0708994859.HKD","LU1035775433.USD","IE00BQXX3C00.GBP","LU1803068979.SGD","LU2023250504.SGD","LU0106261372.USD","LU0950375773.USD","LU0310800379.SGD","LU1642822529.SGD","NQmain","SG9999014906.USD","IE00BKDWB100.SGD","LU0557290698.USD","LU0390134368.USD","LU0289961442.SGD","BK4106","LU0957808578.USD","LU2746668461.USD","IE00B1BXHZ80.USD","LU0345774391.USD","LU0640476718.USD","GB00B4LPDJ14.GBP","LU0320765059.SGD","LU0426417589.USD","LU1814569148.SGD","SG9999018865.SGD","LU1267930573.SGD","LU0057025933.USD","LU2242649171.HKD","SGXZ51526630.SGD","LU2023251221.USD","LU1823568750.SGD","LU2023250843.SGD","GB00B4QBRK32.GBP","SG9999000418.SGD","SGXZ81514606.USD","IE00B19Z9505.USD","LU2471134952.CNY","LU1670627923.USD","LU0965508806.USD","LU2237438978.USD","LU0426412945.USD","LU0511384066.AUD","LU1934455277.USD","LU0353189680.USD","LU0096362180.USD","LU1670628061.USD","LU2506951958.HKD","LU0689626769.HKD","BK4534","LU0787776722.HKD","LU1623119135.USD","LU0234572021.USD","SG9999014914.USD","LU2764263039.SGD","LU0316494557.USD","LU0348723411.USD","LU1935042991.SGD","LU0472753341.HKD","LU0124676726.USD","LU1064131342.USD","LU2764262908.HKD","LU1815333072.USD","LU1791710400.SGD","LU0256863902.USD","LU0965509010.AUD","LU1228905540.USD","LU0444971666.USD","LU1974910355.USD","LU2111349929.HKD","LU0056508442.USD","LU0109392836.USD","LU1852331112.SGD","LU0476273544.USD","LU1935042215.USD","LU1046421795.USD","LU0128525929.USD","LU0545562505.USD","LU0690374615.EUR","BK4139","LU0215105999.USD","LU0154236417.USD","LU1934455194.USD","LU0942090050.USD","LU0187121727.USD","LU0823417653.USD","LU2471134796.USD","LU0354030511.USD","LU1989772923.USD","IE00BQXX3F31.USD","LU1037948541.HKD","LU1804176565.USD","LU0289739343.SGD","LU1236620834.HKD","LU0157215616.USD","LU0029864427.USD","BK4598","LU2506952170.USD","LU1037948897.HKD","LU1435385759.SGD","LU0234570918.USD","LU2326559502.SGD","LU0672654240.SGD","IE00B19Z8X17.USD","IE00B19Z8W00.USD","LU2106854487.HKD","LU0289941410.SGD","LU2089283258.USD","LU0868494708.USD","LU1116320901.HKD","LU2471134879.HKD","LU1691799644.USD","IE00BWXC8680.SGD","LU2404859667.USD","BK4588","LU0289960550.SGD","LU1934455863.HKD","SG9999001424.SGD","XENE","LU0158827948.USD","LU0342679015.USD","BK4535","LU0345774631.USD","BK4585","LU0823417737.USD","LU0642271901.SGD","IE00BKVL7J92.USD","LU1121112475.USD","LU0965509101.SGD","LU0256863811.USD","LU0265550946.USD","LU0861579265.USD","LU1228905037.USD","LU0823434740.USD","LU1267930730.SGD","LU1429558221.USD","LU1633808545.USD","LU1712237335.SGD","LU1815336760.USD","LU0158827781.USD","LU2461242641.AUD","V","LU0823421333.USD","LU1935042488.USD","LU0127658192.USD","LU0823434583.USD","LU2087625088.SGD","LU1791710582.SGD","LU2764263203.CNY","LU0690374961.EUR","LU1917777945.USD","BK4533","LU1988902786.USD","LU2097829019.USD","LU2750360997.AUD","LU2471134523.USD","LU0097036916.USD","LU0417517546.SGD","LU0683600562.USD","LU0109391861.USD","LU0354030438.USD","LU2720916845.USD","LU0265550359.USD","LU1316542783.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148572302","title":"Xenon制药第三季度净亏损9,089.6万美元，接近IBES预期的9,130万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148572302","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148572302?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:30","pubTimestamp":1763569816,"startTime":"0","endTime":"0","summary":"11月3日——Xenon制药第三季度运营费用为963.36万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518063352","title":"Xenon制药盘中异动 大幅下跌5.00%报34.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518063352","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518063352?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:40","pubTimestamp":1741628437,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时40分，Xenon制药股票出现异动，股价大幅下挫5.00%。截至发稿，该股报34.68美元/股，成交量15.2499万股，换手率0.20%，振幅5.75%。Xenon制药股票所在的生物技术行业中，整体涨幅为0.83%。其相关个股中，Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为5311.24%、3824.09%、989.67%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、58.34%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031101403796406796&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031101403796406796&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XENE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517082437","title":"Xenon制药2024财年实现净利润-2.34亿美元，同比减少28.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517082437","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517082437?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363252,"startTime":"0","endTime":"0","summary":"3月8日，Xenon制药公布财报，公告显示公司2024财年净利润为-2.34亿美元，同比减少28.57%；其中营业收入为0.00美元，每股基本收益为-3.01美元。从资产负债表来看，Xenon制药总负债3.12亿美元，其中短期债务1.37百万美元，资产负债比为3.42，流动比率为0.18。机构评级：截至2025年3月8日，当前有16家机构对Xenon制药目标价做出预测，其中目标均价为57.81美元，其中最低目标价为42.00美元，最高目标价为65.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000225abed6691&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000225abed6691&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516184665","title":"Xenon制药盘中异动 临近收盘股价大跌5.00%报35.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516184665","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516184665?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:49","pubTimestamp":1741034991,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时49分，Xenon制药股票出现异动，股价快速跳水5.00%。截至发稿，该股报35.17美元/股，成交量57.2635万股，换手率0.75%，振幅7.16%。机构评级方面，在所有17家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。Xenon制药股票所在的生物技术行业中，整体跌幅为0.07%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304044951a25da8cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304044951a25da8cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514105378","title":"Xenon制药盘中异动 股价大跌6.00%报36.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514105378","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514105378?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753092,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Xenon制药股票出现波动，股价快速跳水6.00%。截至发稿，该股报36.01美元/股，成交量3487股，换手率0.00%，振幅0.00%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-62.79百万美元，每股收益-0.81美元，毛利-669000.00美元，市盈率-13.17倍。机构评级方面，在所有17家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。Xenon制药股票所在的生物技术行业中，整体涨幅为0.02%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223132abe0ea36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223132abe0ea36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116368381","title":"氙气制药公司2024年第四季度GAAP每股收益$(0.84)优于$(0.86)预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1116368381","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116368381?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:04","pubTimestamp":1740690277,"startTime":"0","endTime":"0","summary":"氙气制药公司报告季度亏损每股$，优于分析师共识$的预期，超出2.33%。与去年同期每股亏损$相比，这减少了31.25%。以上内容来自Benzinga Earnings专栏，原文如下：Xenon Pharmaceuticals  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 2.33 percent. This is a 31.25 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"氙气制药公司2024年第四季度GAAP每股收益$(0.84)优于$(0.86)预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514586612","title":"Xenon制药盘中异动 股价大涨5.09%报39.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514586612","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514586612?lang=zh_cn&edition=full","pubTime":"2025-02-27 02:20","pubTimestamp":1740594023,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日02时20分，Xenon制药股票出现波动，股价急速拉升5.09%。截至发稿，该股报39.57美元/股，成交量27.5217万股，换手率0.36%，振幅5.30%。Xenon制药股票所在的生物技术行业中，整体跌幅为0.46%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Renovaro Inc.涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6430.38%、270.06%、241.41%，振幅较大的相关个股有Enveric Biosciences, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Pds Biotechnology Corporation，振幅分别为194.07%、49.18%、44.44%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227022024abde1f83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227022024abde1f83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XENE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510358484","title":"Xenon Pharmaceuticals(XENE.US)获德银首次覆盖，给予买入评级, 目标价67.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510358484","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510358484?lang=zh_cn&edition=full","pubTime":"2025-02-12 02:11","pubTimestamp":1739297470,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals(XENE.US)获德银首次覆盖，给予买入评级, 目标价67.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12021148092642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2500497512","title":"Xenon制药盘中异动 早盘大幅拉升5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500497512","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500497512?lang=zh_cn&edition=full","pubTime":"2025-01-02 23:19","pubTimestamp":1735831166,"startTime":"0","endTime":"0","summary":"北京时间2025年01月02日23时19分，Xenon制药股票出现波动，股价快速上涨5.05%。截至发稿，该股报41.18美元/股，成交量6.4519万股，换手率0.08%，振幅4.41%。Xenon制药股票所在的生物技术行业中，整体涨幅为0.96%。其相关个股中，Revelation Biosciences Inc C/Wts 10/01/2027 、知临集团、Revelation Biosciences, Inc.涨幅较大，Revelation Biosciences, Inc.、知临集团、Onconetix, Inc.较为活跃，换手率分别为1058.06%、85.94%、45.92%，振幅较大的相关个股有Revelation Biosciences, Inc.、Revelation Biosciences Inc C/Wts 10/01/2027 、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为121.48%、98.57%、78.14%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102231926a2130dbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102231926a2130dbf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xenon-pharma.com;investor.xenon-pharma.com","stockEarnings":[{"period":"1week","weight":0.0233},{"period":"1month","weight":0.0772},{"period":"3month","weight":0.4453},{"period":"6month","weight":0.4144},{"period":"1year","weight":0.7826},{"period":"ytd","weight":0.3137}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Xenon Pharmaceuticals Inc.依据商业公司法（不列颠哥伦比亚省）在其前身（Xenon Bioresearch Inc.）名义下于1996年11月5日在不列颠哥伦比亚省注册成立。该公司是一家为孤儿发现和开发分化疗法管道的临床阶段生物制药公司，该公司打算为了更大的市场使自身商业化，并打算与全球制药公司建立合作伙伴。为了开发对症药物该公司通过研究罕见的具有极端特质的人类疾病，包括离子通道突变引发的疾病，又称为离子通道基因突变疾病建立了一个核心启用发现平台。公司拥有一个集成的平台，包括人类遗传学，小分子药物发现和临床前和临床开发等内部功能。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.008322},{"month":2,"riseRate":0.75,"avgChangeRate":0.076063},{"month":3,"riseRate":0.25,"avgChangeRate":-0.040327},{"month":4,"riseRate":0.583333,"avgChangeRate":0.022033},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.037416},{"month":6,"riseRate":0.454545,"avgChangeRate":0.032291},{"month":7,"riseRate":0.363636,"avgChangeRate":0.01913},{"month":8,"riseRate":0.727273,"avgChangeRate":0.07504},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.05886},{"month":10,"riseRate":0.454545,"avgChangeRate":0.054946},{"month":11,"riseRate":0.727273,"avgChangeRate":0.050412},{"month":12,"riseRate":0.666667,"avgChangeRate":0.089745}],"exchange":"NASDAQ","name":"Xenon制药","nameEN":"Xenon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xenon制药(XENE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Xenon制药(XENE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Xenon制药,XENE,Xenon制药股票,Xenon制药股票老虎,Xenon制药股票老虎国际,Xenon制药行情,Xenon制药股票行情,Xenon制药股价,Xenon制药股市,Xenon制药股票价格,Xenon制药股票交易,Xenon制药股票购买,Xenon制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xenon制药(XENE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Xenon制药(XENE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}